Insight

Priyamvada Maitre: Is RT and ADT Good Enough in PSMA-Staged High-Risk Prostate Cancer?

Priyamvada Maitre/researchgate.net

May 26, 2025, 17:10

Priyamvada Maitre: Is RT and ADT Good Enough in PSMA-Staged High-Risk Prostate Cancer?

Priyamvada Maitre, Radiation Oncologist at the Department of Radiation Oncology, Tata Memorial Centre, shared a post on X about a paper she co-authored with colleagues published in Prostate Cancer and Prostatic Diseases:

“New Paper. Systemic treatment high in PSMA-staged high-risk prostate cancer – is RT+ADT good enough? Congrats Ashesh! Builds on the ESTRO 2025 debate on radiotherapy vs immunotherapy for high-risk prostate cancer by Vedang Murthy. Check out the new trial RELAX on this Q!”

Title: Abiraterone for “STAMPEDE-Like” cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?

Authors: Vedang Murthy, Asesh Samanta, Priyamvada Maitre, Prashant Nayak, Pallavi Singh, Archi Agrawal, Amit Joshi, Gagan Prakash.

You can read the Full Article in Prostate Cancer and Prostatic Diseases.

Priyamvada Maitre: Is RT and ADT Good Enough in PSMA-Staged High-Risk Prostate Cancer?

More posts featuring Priyamvada Maitre.

abiraterone Amit Joshi Archi Agrawal Asesh Samanta cancer ESTRO 2025 Gagan Prakash OncoDaily Oncology Pallavi Singh Prashant Nayak Priyamvada Maitre prostate cancer PSMA PET Vedang Murthy

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply